Tyzeka Novartis - Treatment for Chronic Hepatitis B
Tyzeka is a synthetic thymidine nucleoside analogue indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.Posted: October 2006
Related Articles:
- Idenix and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for the Treatment of Chronic Hepatitis B - January 3, 2006
Tyzeka (telbivudine) FDA Approval History
